The UK-based firm recently launched its Nadia system, which is compatible with the Drop-seq protocol, and plans to develop additional applications.
As part of a new partnership, Partek Flow NGS analysis software will help researchers access single-cell RNA sequences without the need for bioinformatics expertise.
A new assay uses digital loop-mediated isothermal amplification (dLAMP) to perform phenotypic antibacterial susceptibility testing in 30 minutes.
The company acquired GnuBio, which was developing a droplet-based sequencing platform, in 2014 for $39.7 million in cash and $10 million in contingent payments.
With growing interest in single-cell sequencing, researchers are looking to increase the throughput while also reducing cost.
The aim of the project, called Metafluidics, is to replace cumbersome conventional approaches with a cheaper, faster, and higher-throughput microfluidics platform.
The technology uses DNAzyme-based sensors, fluorescent biomarkers, and a high-throughput particle counter to rapid identify rare targets in complex raw samples.
Researchers from the University of Michigan are beginning to use Drop-Seq to characterize human kidney cells.
After scrapping initial plans to develop a diagnostic instrument, the company has been working for several years to advance its single-cell droplet platform for targeted drug development.
The method simplifies previous techniques, and preliminary testing using a microfluidic device indicates it could ultimately be used in low-resource settings.
A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.
A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.
In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.
A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.